[177Lu]Lu-PSMA is a form of radionuclide therapy whereby the isotope lutetium-177 (177Lu) is attached to a prostate-specific membrane antigen (PSMA) radioligand to enable targeted delivery of radiation to prostate cancer cells via beta-particle emission. Here, FOLH1 is linked to prostate cancer.